OncoDNA SA Revenue and Competitors
Estimated Revenue & Valuation
- OncoDNA SA's estimated annual revenue is currently $10.4M per year.
- OncoDNA SA's estimated revenue per employee is $155,000
Employee Data
- OncoDNA SA has 67 Employees.
- OncoDNA SA grew their employee count by -12% last year.
OncoDNA SA's People
Name | Title | Email/Phone |
---|---|---|
1 | Global Alliances Manager | Reveal Email/Phone |
OncoDNA SA Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is OncoDNA SA?
OncoDNA is a theranostic and genomic company with renown expertise in precision oncology. The company provides comprehensive testing of cancer biomarkers (DNA, RNA and proteins) on solid and liquid biopsies as well NGS data interpretation services to oncologists, research institutes and biopharmaceutical companies across the globe. The company headquarters are based in Belgium, and its two entities – IntegraGen, a company specializing in the decryption of the human genome and Biosequence – are headquartered in France and Spain, respectively. The group employs approx. 115 employees in 9 countries, works with an international network of 35 distributors and collaborates with one European-based and one US-based subcontracted accredited laboratories.
keywords:N/AN/A
Total Funding
67
Number of Employees
$10.4M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.5M | 87 | 28% | N/A |
#2 | $14.9M | 96 | 37% | $83.7M |
#3 | $29.7M | 110 | 1% | N/A |
#4 | $28.7M | 185 | 5% | N/A |
#5 | $36.8M | 190 | 42% | $249.7M |